Neurology

The approval indicates ocrelizumab for RRMS in patients older than 10 years who weigh 55 pounds or more and is supported by data from the OPERETTA II study.

The FDA approved dextromethorphan hydrobromide-bupropion hydrochloride for agitation associated with dementia due to Alzheimer disease.

6-month INFUSE data show eptinezumab improves migraine outcomes, including headache days and patient-reported measures, even after prior CGRP failures.

The TRIDENT trial shows a once-daily triple BP pill after intracerebral hemorrhage improves control and lowers recurrent stroke and cardiovascular events.

Older adults with both anemia and elevated neurofilament light chain levels faced a more than 3.5-fold increased risk of developing dementia.

New AHA/ASA stroke guidance widens thrombolysis and EVT access, eases imaging, and updates BP/glucose targets—what frontline teams need now.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Gerontological GSA and AAFP explain digital cognitive tests for Alzheimer/dementia, EHR-ready, repeatable, supports KAER care in primary care.

New data highlight digital dementia risk scores, plasma p-tau217 prediction, and patient-centered endpoints in Alzheimer disease research.

Booster-backed speed-of-processing brain training links to lower Alzheimer disease and dementia diagnoses, suggesting modest computer exercises may delay decline.

Centanafadine's FDA priority review signals potential innovation in ADHD treatment, offering a new nonstimulant option for diverse patient needs.

Clevenger explains how better recognition of agitation in Alzheimer disease, and stronger caregiver–clinician communication, can meaningfully improve outcomes.

This episode reviews intranasal epinephrine use, pediatric atopic dermatitis data, dementia screening tools, adolescent TMS, and oral PCSK9 therapy.

Your daily dose of the clinical news you may have missed.

Results from the SPACE clinical trial showed fremanezumab reduced monthly migraine days versus placebo in children and adolescents with episodic migraine.

New data from the DROP-AD study suggests that dried blood spots could revolutionize screening approaches for clinical trials.

Your daily dose of the clinical news you may have missed.

The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026.

Take a quick look back at developments this year with our higlights of acceleration of DMTs, particularly focusing on anti-amyloid antibodies and novel oral agents.

A multidisciplinary panel of neurologists, geriatricians, and researchers examined how early identification, equitable access, and value-based models could reshape Alzheimer disease care.

Your daily dose of the clinical news you may have missed.

The mobile-based program targets cognitive processes underlying attention and is intended for use alongside medication, therapy, or education.

Missed endpoints in midstage tau trials are reshaping the Alzheimer pipeline, with growing focus on inflammatory and vascular pathways. Review them here.